Wednesday, May 13, 2009
Chem Biol Interact. 2009 May 5. [Epub ahead of print]
- Andrographolide could inhibit human colorectal carcinoma Lovo cells migration and invasion via down-regulation of MMP-7 expression.
Shi MD, Lin HH, Chiang TA, Tsai LY, Tsai SM, Lee YC, Chen JH.
Pathology and Laboratory Medicine, Yongkang Veterans Hospital, Tainan, Taiwan; Department of Medical Laboratory and Biotechnology Science, College of Health Sciences Kaohsiung Medical University, Kaohsiung, Taiwan.
Andrographolide (Andro), a diterpenoid lactone isolated from a traditional herbal medicine Andrographis paniculata, is known to possess multiple pharmacological activities. In our previous study, Andro had been shown to have potent anti-cancer activity against human colorectal carcinoma Lovo cells by inhibiting cell-cycle progression. To further investigate the mechanism basis for the anti-cancer properties of Andro, it was used to examine the effect on migration and invasion in Lovo cells. The results of wound-healing assay and in vitro transwell assay revealed that Andro inhibited dose-dependently the migration and invasion of lovo cells under non-cytotoxic concentrations. Using zymographic assay and RT-PCR, the results revealed that Andro diminished the activity and the mRNA and protein levels of MMP-7, but not MMP-2 or MMP-9. The down-regulation of MMP-7 appeared to be via the inactivation of activator protein-1 (AP-1) since the treatment with Andro suppressed the nuclear protein level of AP-1, which was accompanied by a decrease in DNA binding level of the factor. Taken together, these results indicated that Andro reduces the MMP-7-mediated cellular events in Lovo cells, and provided a new mechanism for its anti-cancer activity.
PMID: 19426720 [PubMed - as supplied by publisher]
Leave your response